Drug Review Reorganization Boosts Advisory Role Of Medical Imaging Division
Executive Summary
FDA's reorganization of its drug review divisions will allow the Office of New Drugs' medical imaging staff to assume a broader role in consulting on trials that use medical images as an endpoint
You may also be interested in...
Oncology Drug Reviews To Be Restructured As Office Shifts Away From Divisions Organized Around Molecule Size
FDA's Office of Oncology Drug Products is undergoing a reorganization aimed at making its structure more similar to the rest of the review offices in the Center for Drug Evaluation and Research
Oncology Drug Reviews To Be Restructured As Office Shifts Away From Divisions Organized Around Molecule Size
FDA's Office of Oncology Drug Products is undergoing a reorganization aimed at making its structure more similar to the rest of the review offices in the Center for Drug Evaluation and Research
FDA, Imaging Industry Hear Advice On Radiation Safety Improvements
Groups representing radiologists, imaging technicians and physicists are urging industry to offer more tools to protect patients from potential radiation overexposure during medical imaging